Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 1.00 |
| ▸ | FLT1 | P17948 | 9/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.75 |
| ▸ | FLT4 | P35916 | 3/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | RET | P07949 | 4/20 | 0.45 |
| ▸ | KIF5B | P33176 | 4/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5245396 | 0.91 | KDR (0.83) | KDRFLT1FGFR1FLT4FGFR2 | |
| SCHEMBL1194359 | 0.89 | KDR (0.81) | KDRFLT1FGFR1FLT4FGFR2 | |
| SCHEMBL6099096 | 0.89 | KDR (0.79) | KDRFLT1FGFR1FLT4FGFR2 | |
| SCHEMBL6098452 | 0.87 | KDR (0.77) | KDRFLT1FGFR1FLT4FGFR2 | |
| SCHEMBL6097907 | 0.86 | FLT1 (0.75) | KDRFLT1FGFR1FLT4FGFR2 | |
| SCHEMBL6432152 | 0.85 | FLT1 (1.00) | KDRFLT1FGFR1FLT4FGFR2 | |
| SCHEMBL6098898 | 0.85 | KDR (0.74) | KDRFLT1FGFR1FLT4FGFR2 | |
| Hydrochloric Acid SCHEMBL6431098 | 0.85 | FLT1 (0.98) | KDRFLT1FGFR1FLT4FGFR2 | |
| SCHEMBL6095959 | 0.84 | KDR (0.73) | KDRFLT1FGFR1FLT4FGFR2 | |
| SCHEMBL6098105 | 0.84 | FLT1 (1.00) | KDRFLT1FGFR1FLT4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087602-B2 | Cinnoline derivatives and use as medicine | ASTRAZENECA UK LIMITED (GB) | 2006-08-08 | — | — | US | claimed |
| EP-0888310-B1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | EP | claimed |
| WO-2005037259-A2 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF NEOPLASIA COMPRISING A COX-2 INHIBITOR IN COMBINATION WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | US | claimed |
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | ZENECA LIMITED | 2003-10-23 | — | — | US | claimed |
| US-6514971-B1 | For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans | ZENECA LIMITED (GB) | 2003-02-04 | — | — | US | claimed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | claimed |
| US-7087602-B2 | Cinnoline derivatives and use as medicine | ASTRAZENECA UK LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| EP-0888310-B1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | EP | disclosed |
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | ZENECA LIMITED | 2003-10-23 | — | — | US | disclosed |
| US-6514971-B1 | For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans | ZENECA LIMITED (GB) | 2003-02-04 | — | — | US | disclosed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | VEGFA, CNR1, CCR7 | KDR 13/4885FLT1 5/4885FGFR1 559/4885 |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | EGFR, PTGFR, ERBB2 | KDR 213/4885FLT1 609/4885FGFR1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.